Dental Safety Profile of High-Dose Radioiodine Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

202 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-09-30

Study Completion Date

2006-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We aim to assess the incidence of oral and dental adverse events after high-dose radioiodine therapy for differentiated thyroid cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sialadenitis and xerostomia are the most frequent adverse events of high-dose radioiodine therapy. Saliva has vital functions in maintaining periodontal and oral health. Therefore, xerostomia not only impairs quality of life permanently, but may also increase the risk of caries and tooth extractions. Nevertheless, despite more than 6 decades of radioiodine therapy for thyroid cancer, large studies on long-term oral adverse events are still lacking. In the present study, we investigate the influence of high-dose radioiodine therapy on the long-term oral health.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Radioiodine, Thyroid Cancer, Sialadenitis, Xerostomia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radioiodine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* histologically confirmed differentiated thyroid cancer
* status after total thyroidectomy
* status after subsequent high-dose radioiodine treatment
* regular follow-up by a board-certified dentist
* a minimum follow-up of 1 year after radioiodine therapy.

Exclusion Criteria

* anaplastic thyroid cancer

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Beat Müller, MD

Role: STUDY_DIRECTOR

Division of Endocrinology, University Hospital Basel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

171074

Identifier Type: -

Identifier Source: org_study_id